Japan's MBL Transfers Protein Test Tech to Agappe Diagnostics in India

India had to rely on the tests by imports for estimating proteins and is now being facilitated with a technology transfer from Medical and Biological Laboratories (MBL), Japan, to Agappe Diagnostics, Kochi. The advancements in the tests generally open doors towards disease detection and disorder diagnosis based on specific protein test estimation like kidney diseases, sepsis, infertility, and diabetes. According to Agappe sources, the technology transfer assures them of a stable supply chain in regulatory conformance with global standards for reagent manufacture.

This collaboration is a huge boost to the production of diagnostic reagents, thus strengthening Agappe's position within India as one of the leaders in the healthcare sector. Also, it offers the opportunity for the first domestic production of these crucial reagents.

Agappe Diagnostics Ltd. is an Indian manufacturer of diagnostic reagents and equipment with 70,000 customers in 90 countries. With the support of technical knowledge and innovations from MBL, Agappe hopes to penetrate the specific protein testing market and push into new regions, particularly Africa, said Thomas John, managing director of Agappe Diagnostics Ltd.

Founded in 1969, MBL was Japan's first antibody-manufacturing company, still at the forefront of diagnostic innovation. The company specializes in autoimmune disease diagnostics and operates a full in vitro diagnostics (IVD) system, from research to clinical studies to regulatory approvals, manufacture, and global distribution.

With innovative IVD solutions, Agappe Diagnostics has a complete product range that includes not just clinical chemistry and immunology but also hematology, molecular diagnostics, and point-of-care testing (POCT).